<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368300</url>
  </required_header>
  <id_info>
    <org_study_id>RBM-PAP-2011/86</org_study_id>
    <nct_id>NCT03368300</nct_id>
  </id_info>
  <brief_title>Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans</brief_title>
  <acronym>CAP</acronym>
  <official_title>Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Pointe-a-Pitre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Pointe-a-Pitre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to estimate the frequency and to characterize clinically
      atypical parkinsonism in the French West Indies and Guyana.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An atypical akineto-rigid parkinsonian syndrome, unresponsive to L-dopa has been evidenced in
      Guadeloupe. Abnormally frequent, this progressive supranuclear palsy (PSP)-like syndrome
      represents a new clinical entity. Unlike in classical PSP 70% of patients have myoclonus, 59%
      hallucinations, 78% REM sleep behavior disorders. Oculomotor pattern differs from classical
      PSP suggesting that cortical dysfunction predominates over brainstem impairments.
      Neuropathological examination in four patients has shown a widespread accumulation of the tau
      protein in the basal ganglia, the midbrain and cortical areas.

      This syndrome has been associated to the regular consumption of food products derived from
      plants of the Annonaceae family, more specifically Annona Muricata (soursop), suggesting a
      toxic origin. We have already confirmed the neurotoxic potential of the lipophilic
      mitochondrial complex I inhibitor annonacin, the major acetogenin in Annona muricata. This
      class of compounds is specific to Annonaceae. Nanomolar concentrations of annonacin induce
      the death of dopaminergic neurons in culture, by impairment of energy production. Chronic
      systemic intoxication of rats with annonacin causes neuronal damage in the same brain regions
      that are damaged in patients with atypical parkinsonism. These results greatly suggest that
      the consumption of annonacea might contribute to the pathogenesis of the disease. The H1
      subhaplotype in tau gene associated with PSP in Caucasians did not confer risk for PSP-like
      atypical parkinsonism in Guadeloupe.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2012</start_date>
  <completion_date type="Anticipated">August 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The primary aim of this study is to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana.
This study has been designed as epidemiological, multicentric transversal descriptive and longitudinal prospective study with biological collection and post-mortem neuropathological sub-study of brain tissue.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Not masking, 2 groups parallel</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana</measure>
    <time_frame>At the end of the Period of inclusion, around 5-6 years</time_frame>
    <description>Collection of :
administrative and socioeconomic data, medical consultation with video recording , recording oculomotor to the atypical</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to compare the proportion of atypical forms within parkinsonian syndromes;</measure>
    <time_frame>At the end of the Period of inclusion, around 5-6 years</time_frame>
    <description>Collection of :
administrative and socioeconomic data, medical consultation with video recording , recording oculomotor to the atypical neuropsychological balance assessment ,
Clinical diagnostic criteria
Compilation of functional indicators of motor and cognitive autonomy and Collection of intercurrent medical events
Food and exposure questionnaire
Neuropsychological assessment
Recording of oculomotor movements and Post-mortem analysis
biological collection (plasma, DNA, serum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to characterize the entity &quot;Parkinson-dementia complex&quot; described in Guadeloupe ; to characterize the entity &quot;Parkinson-dementia complex&quot; described in Guadeloupe ;</measure>
    <time_frame>Through study completion, an average of 11 years</time_frame>
    <description>Compilation of functional indicators of motor and cognitive autonomy and Collection of intercurrent medical events.
Collection of :
administrative and socioeconomic data, medical consultation with video recording , recording oculomotor to the atypical neuropsychological balance assessment ,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the natural history of typical and atypical forms of parkinsonism by following a cohort of the incident cases only;</measure>
    <time_frame>Through study completion, an average of 11 years</time_frame>
    <description>Neuropsychological assessment Food and exposure survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the implication of a toxic alimentary factor in the etiopathogenesis of atypical forms and compare the results in the 3 areas (Guadeloupe, Guyane, Martinique);</measure>
    <time_frame>Through study completion, an average of 11 years</time_frame>
    <description>Neuropsychological assessment Food and exposure survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the latency of cognitive decline in idiopathic Parkinson's disease in the 3 areas ;</measure>
    <time_frame>Through study completion, an average of 11 years, post-mortem analysis after death if applicable</time_frame>
    <description>Recording of oculomotor movements and Post-mortem analysis (sampling of blood and cutaneous biopsy to establish a collection of biological samples)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to constitute a biological collection (plasma, DNA, serum).</measure>
    <time_frame>At the end of the Period of inclusion, around 5-6 years</time_frame>
    <description>biological collection (plasma, DNA, serum)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Atypical Parkinsonism</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Parkinson's patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>witnesses: without parkinson's disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects without parkinson's disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical and biological exam</intervention_name>
    <description>The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.
All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors
All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma).</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>witnesses: without parkinson's disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pour les patients :

               1. Patient ou tiers responsable ayant reçu une information sur l'étude et ayant
                  signé le consentement éclairé

               2. Patient âgé de plus de 18 ans

               3. Patient consultant en neurologie ou en gériatrie pour symptomatologie
                  parkinsonienne ou pour troubles cognitifs évocateurs d'une démence à corps de
                  Lewy

               4. Patient domicilié aux Antilles-Guyane

                  Pour les témoins :

               5. Conjoint ou accompagnant ayant reçu une information sur l'étude et ayant signé le
                  consentement éclairé

               6. Personne âgée de plus de 18 ans

               7. Personne ne présentant pas de pathologie d'allure neurodégénérative (Parkinson,
                  démence notamment)

               8. Personne domiciliée aux Antilles-Guyane

        Exclusion Criteria:

        Pour les patients :

          1. Syndrome parkinsonien secondaire (post-traumatique, vasculaire, iatrogène, post
             encéphalitique)

          2. Patient non affilié au régime de sécurité sociale

          3. En cas de difficulté de suivi le patient sera exclu de l'étude longitudinale

        Pour les témoins :

          1. Personnes présentant des troubles cognitifs ou un syndrome parkinsonien diagnostiqué.

          2. Patient non affilié au régime de sécurité sociale -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annie LANNUZEL, PU-PH</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Guadeloupe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Régine EDRAGAS, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Martinique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique MARNET, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>: University Hospital of Guyana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie HAMONY SOTER, Project leader</last_name>
    <phone>0590 93 46 86</phone>
    <phone_ext>+590</phone_ext>
    <email>valerie.soter@chu-guadeloupe.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mélanie PETAPERMAL, Monito manager</last_name>
    <phone>0590 93 46 86</phone>
    <phone_ext>+590</phone_ext>
    <email>melanie.petapermal@chu-guadeloupe.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Guyana</name>
      <address>
        <city>Cayenne</city>
        <zip>97306</zip>
        <country>French Guiana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique MARNET, PH</last_name>
      <phone>05 94 39 51 46</phone>
      <phone_ext>(+0594)</phone_ext>
      <email>domminique.marnet@ch-cayenne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Martinique</name>
      <address>
        <city>Fort-de-France</city>
        <zip>97261</zip>
        <country>Martinique</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Régine EDRAGAS, PH</last_name>
      <phone>05 96 720482</phone>
      <phone_ext>(+596)</phone_ext>
      <email>nakapmireil@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>French Guiana</country>
    <country>Martinique</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>progressive supranuclear palsy</keyword>
  <keyword>Caribbean atypical Parkinsonism</keyword>
  <keyword>Annona Muricata</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

